母体血清胎盘生长因子联合中期唐氏筛查对胎儿生长受限的预测分析

Analysis of Maternal Serum Placental Growth Factor and Second-trimester Down’s Syndrome Screening to Predict Fetal Growth Restriction

目的探讨中期唐氏筛查联合胎盘生长因子(PlGF)对胎儿生长受限(FGR)的预测价值。方法收集2020年6月—2022年1月就诊的单胎妊娠孕妇530例,于妊娠15~20+6周采血检验PlGF,并进行中期唐氏筛查,对各指标进行线性相关性分析和二元logistic回归分析,采用受试者工作特征曲线(ROC)评估模型的性能。结果中期唐氏筛查的3项血清生物标志物与PlGF的相关性均无统计学意义(P>0.05)。ROC曲线提示,联合PlGF和中期唐氏筛查可实现更高的诊断效能(P=0.009),曲线下面积为0.873(95%CI:0.787~0.959),灵敏度为76.0%,特异度为93.2%。结论在中期唐氏筛查的基础上增加PlGF检测,对预测FGR具有临床意义。

Objective It is to assess the predictive value of placental growth factor(PlGF)in combination with second-trimester Down's syndrome screening for fetal growth restriction(FGR).Method 530 pregnant women with singleton pregnancies who visited our hospital from June 2020 to January 2022 were collected,and blood was collected at 15-20+6 weeks of gestation for PlGF and econd-trimester Down's screening;linear correlation analysis and binary logistic analysis were performed for each indicator,and the performance of the model was assessed using the subject's work characteristic curve(ROC).Results The correlation between the three serum biomarkers of second-trimester Down's screening and PlGF was not statistically significant(P>0.05).The ROC curve suggested that higher diagnostic efficacy could be achieved by combining PlGF and midterm Down s screening(P=0.009),with an area under the curve(AUC)of 0.873(95%CI:0.787-0.959),a sensitivity of 76.0% and a specificity was 93.2%.Conclusion The addition of PlGF to the second-trimester Down s syndrome screening in the established obstetrics program has clinical significance in the prediction of FGR.